Resultaten

Artikel
Dit item is dichtgeklapt
Dit item is opengeklapt

Titel: Different PSA assays lead to detection of prostate cancers with identical histological features.
Auteur(s): Yurdakul G, Bangma CH, Blijenberg BG, van Zelst BD, Wildhagen MF, van der Kwast TH, Schroder FH.
Tijdschrift: European urology
Start- en eindpagina: 154 - 158

Titel: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial.
Auteur(s): de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 268 - 273

Titel: European Randomized Screening for Prostate Cancer (ERSPC)Trial; IPSTEG. Large-scale randomized PC screening trials: program performances in the ERSPC trial and the PLCO cancer trial.
Auteur(s): de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagen JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schroder FH.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 237 - 244

Titel: Should we start population screening for prostate cancer?
Auteur(s): Auvinen A, Alexander FE, de Koning HJ, Miller AB.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 377 - 378

Titel: Verificatin bias and the prostate-specific antigen test - is there acase for a lower threshold for biopsy?
Auteur(s): Schröder FH, Kranse R.
Tijdschrift: New England Journal of Medicine
Start- en eindpagina: 393 - 395

Titel: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
Auteur(s): Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 826 - 830

Titel: A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.
Auteur(s): Roobol MJ, Kranse R, van der Cruijsen IW, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 91 - 96

Titel: Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
Auteur(s): Vis AN, van Rhijn BW, Noordzij MA, Schröder FH, van der Kwast TH.
Tijdschrift: Journal of Pathology
Start- en eindpagina: 148 - 154

Titel: Serendipity in detecting desease in low prostate-specific antigen ranges.
Auteur(s): Vis AN, Kranse R, Roobol M, van der Kwast TH, Schröder FH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 384 - 389

Titel: Does PSA screening reduce prostate cancer mortality?
Auteur(s): Vis AN.
Tijdschrift: CMAJ
Start- en eindpagina: 600 - 601

Titel: Screening for prostate cancer.
Auteur(s): Schröder FH.
Tijdschrift: Urology Clinical North America
Start- en eindpagina: 239 - 251

Titel: Guidelines for processing and reporting of prostatic needle biopsies.
Auteur(s): van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF; members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer.
Tijdschrift: Journal of Clinical Pathology
Start- en eindpagina: 336 - 340

Titel: Informed consent for prostate-specific antigen-based screening- European view.
Auteur(s): Ito K, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 20 - 22

Titel: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
Auteur(s): Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ.
Tijdschrift: Journal of the National Cancer Institute
Start- en eindpagina: 868 - 878

Titel: Measuring disease specific quality of life in localized prostate cancer: the Dutch experience.
Auteur(s): Korfage IJ, Essink-Bot ML, Madalinska JB, Kirkels WJ, Litwin MS, de Koning HJ.
Tijdschrift: Quality of Life Res.
Start- en eindpagina: 459 - 464

Titel: Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
Auteur(s): van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH.
Tijdschrift: Journal of the National Cancer Institute
Start- en eindpagina: 1462 - 1466

Titel: The story of the European Randomized Study of Screening for Prostate Cancer.
Auteur(s): Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ; ERSPC.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 1 - 13

Titel: ERSPC: features and preliminary results from the Antwerp study centre.
Auteur(s): Nelen V, Thys G, Neels H, Neetens I, Coebergh JW, Dourcy-Belle-Rose B, Denis L.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 17 - 21

Titel: Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).
Auteur(s): Roobol MJ, Kirkels WJ, Schröder FH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 48 - 54

Titel: Report of the Pathology Committee: false-positive and false-negative diagnoses of prostate cancer.
Auteur(s): Van der Kwast TH, Lopes C, Martikainen PM, Pihl CG, Santonja C, Neetens I, Di Lollo S, Hoedemaeker RF.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 62 - 65

Titel: Determining the cause of death in randomized screening trial(s) for prostate cancer.
Auteur(s): De Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, Van Vliet P, Nelen V, Coebergh JW, Hermans A, Ciatto S, Makinen T.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 71 - 78

Titel: Quality assessment for prostate-specific antigen (PSA)in relation to ERSPC: report of the PSA committee.
Auteur(s): Blijenberg GB, Lilja H, Neels H, Stenman UH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 66 - 70

Titel: Four-year prostate-specific antigen progression in the non-cancer population of the European Randomized Study of Screening for Prostate Cancer.
Auteur(s): Paez A, Lujan M, Raaijmakers R, Berenguer A; ERSPC.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 84 - 87

Titel: Consistency of prostate cancer grading results in screened populations across Europe.
Auteur(s): Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Maatanen L, Pihl CG, Santonja C, Bubendorf L, Neetens I, Di Lollo S, Hoedemaeker RF.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 88 - 91

Titel: The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
Auteur(s): Hoedemaeker RF, Van der Kwast TH, Schröder FH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 92 - 96

Titel: Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revised?
Auteur(s): Essink-Bot ML, Korfage IJ, De Koning HJ.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 101 - 105

Titel: MISCAN: estimating lead-time and over-detection by simulation.
Auteur(s): Draisma G, De Koning HJ.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 106 - 111

Titel: Monitoring the ERSPC trial.
Auteur(s): De Koning HJ, Hakulinen T, Moss SM, Adolfsson J, Smith PH, Alexander FE; ERSPC.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 112 - 114

Titel: European Randomized Study of Screening for Prostate Cancer: achievements and presentation.
Auteur(s): Roobol MJ, Schröder FH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 117 - 122

Titel: Priorities in future research in prostate cancer screening.
Auteur(s): Schröder FH.
Tijdschrift: European Journal of Epidemiology
Start- en eindpagina: 1021 - 1023

Titel: PSA-vergelijkbaarheid: standaardisatie of harmonisatie?
Auteur(s): Van Zelst BD, Blijenberg BG.
Tijdschrift: European urology
Start- en eindpagina: 26 - 32

Titel: Comparison of two assays for human killikrein 2.
Auteur(s): Blijenberg BG, Wildhagen MF, Bangma CH, Finlay JA, Vaisanen V, Schröder FH.
Tijdschrift: Clin Chem.
Start- en eindpagina: 243 - 247

Titel: Watchful waiting in prostate cancer: review and policy proposals.
Auteur(s): Schröder FH, de Vries SH, Bangma CH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 851 - 859

Titel: Effective PSA contaminatin in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Auteur(s): Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, de Koning HJ.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 394 - 399

Titel: Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Auteur(s): Raaijmakers R, Wildhagen MF, Ito K, Paez A, de Vries SH, Roobol MJ, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 316 - 320

Titel: Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Auteur(s): Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 309 - 313

Titel: The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
Auteur(s): Bangma CH, Wildhagen MF, Yurdakul G, Schröder FH, Blijenberg BG.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 720 - 724

Titel: Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Auteur(s): Postma R, Roobol M, Schröder FH, van der Kwast TH.
Tijdschrift: Cancer
Start- en eindpagina: 968 - 975

Titel: Update on screening and early detection of prostate cancer.
Auteur(s): Otto SJ, de Koning HJ.
Tijdschrift: Current Opinion Urology
Start- en eindpagina: 151 - 156

Titel: No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater.
Auteur(s): ERSPC, Rotterdam.
Tijdschrift: Urology
Start- en eindpagina: 892 - 897

Titel: Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-politive PSA results in prostate cancer screening.
Auteur(s): Finne P, Finne R, Bangma CH, Hugosson J, Hakama M, Auvinen A, Stenman U-H.
Tijdschrift: Human Molecular Genetics
Start- en eindpagina: 1303 - 1313

Titel: Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
Auteur(s): Postma R, Roobol M, Schröder FH, van der Kwast TH.
Tijdschrift: Prostate
Start- en eindpagina: 260 - 266

Titel: Prostate cancer detection in the prostate specific antigen on tumor detection and tumor aggressiveness.
Auteur(s): Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schröder FH.
Tijdschrift: Journal of Urology
Start- en eindpagina: 2245 - 2249

Titel: Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-controle study ..... with a 4-year interval.
Auteur(s): Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH.
Tijdschrift: Journal of Clinical Endocrinologic Metabolism
Start- en eindpagina: 4391 - 4396

Titel: Prostate volume ultrasonography: the influence of transabdominal versus transrectal approach, device type and operator.
Auteur(s): Huang Foen Chung JW, de Vries SH, Raaijmakers R, Postma R, Bosch JL, van Mastrigt R.
Tijdschrift: European Urology
Start- en eindpagina: 352 - 356

Titel: Detection characteristics in randomized prostate screening.
Auteur(s): Schröder FH, Roobol MJ.
Tijdschrift: Clinical Cancer Research
Start- en eindpagina: 5641 - 5642

Titel: Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: selfselection bias?
Auteur(s): Otto SJ, Schröder FH, de Koning HJ.
Tijdschrift: Journal of Medical Screening
Start- en eindpagina: 89 - 92

Titel: Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
Auteur(s): de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH.
Tijdschrift: Journal of Urology
Start- en eindpagina: 2193 - 2196

Titel: Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
Auteur(s): Gosselaar C, Roobol MJ, Schröder FH.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 231 - 237

Titel: Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Auteur(s): Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH.
Tijdschrift: Cancer
Start- en eindpagina: 708 - 716

Titel: Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Auteur(s): Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
Tijdschrift: Cancer
Start- en eindpagina: 242 - 250

Titel: Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
Auteur(s): Postma R, Schröder FH, van der Kwast TH.
Tijdschrift: Urology
Start- en eindpagina: 745 - 749

Titel: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Auteur(s): Schröder FH.
Tijdschrift: Canadian Journal of Urology
Start- en eindpagina: 2 - 6

Titel: Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting?
Auteur(s): ERSPC, section Rotterdam.
Tijdschrift: Urology
Start- en eindpagina: 343 - 346

Titel: Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
Auteur(s): de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH.
Tijdschrift: Urology
Start- en eindpagina: 926 - 930

Titel: Rotterdam randomized pilot studies of screening for prostate cancer-an overview after 10 years.
Auteur(s): Schröder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, Van der Kwast TH, Kirkels WJ, Bangma CH.
Tijdschrift: Journal of the National Cancer Institute
Start- en eindpagina: 696 - 0

Titel: Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
Auteur(s): van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schroder FH.
Tijdschrift: Journal of Urology
Start- en eindpagina: 121 - 125

Titel: 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized study of screening for prostate cancer, section Rotterdam.
Auteur(s): Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.
Tijdschrift: Journal of Urology
Start- en eindpagina: 489 - 494

Titel: Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
Auteur(s): Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schroder FH.
Tijdschrift: Canadian Journal of Urology
Start- en eindpagina: 16 - 20

Titel: Prostate cancer diagnosis: the impact on patients'mental health.
Auteur(s): Korfage IJ, de Koning HJ, Roobol M, Schroder FH, Essink-Bot ML.
Tijdschrift: European Journal of Cancer Prevention
Start- en eindpagina: 165 - 170

Titel: Prostate cancer: risks and benefits of screening.
Auteur(s): Roemeling S, Schroder FH.
Tijdschrift: National Clinical Practice of Urology
Start- en eindpagina: 4 - 5

Titel: Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
Auteur(s): Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijsen-Koeter, van der Kwst TH, Schroder FH; (ERSPC).
Tijdschrift: Prostate
Start- en eindpagina: 625 - 631

Titel: A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
Auteur(s): Roobol MJ, Schroder FH, Kranse R; ERSPC, Rotterdam.
Tijdschrift: Prostate
Start- en eindpagina: 604 - 612

Titel: Does PSA velocity predict prostate cancer in pre-screened populations?
Auteur(s): Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH.
Tijdschrift: European Urology
Start- en eindpagina: 460 - 465

Titel: Words of wisdom: Comment on prostate-specific Antigen levels in the United States: implications of various definitions for abnormal.
Auteur(s): Schroder FH, Roobol MJ.
Tijdschrift: European Urology
Start- en eindpagina: 412 - 413

Titel: Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
Auteur(s): Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schroder FH.
Tijdschrift: Journal of Urology
Start- en eindpagina: 1332 - 1336

Titel: Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized screening study for Prostate Cancer.
Auteur(s): van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Maatanen L, Santonja C, Moss S, Schroder FH.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 2538 - 2542

Titel: Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas.
Auteur(s): Postma R, van Marion R, van Duin M, Vissers KJ, Wink JC, Schroder FH, Tanke HJ, Szuhai K, van der Kwast TH, van Dekken H.
Tijdschrift: Anticancer Res.
Start- en eindpagina: 1193 - 1200

Titel: Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of screening for prostate cancer (ERSPC).
Auteur(s): Roemeling S, Roobol MJ, Gosselaar C, Schröder FH.
Tijdschrift: Prostate
Start- en eindpagina: 1076 - 1081

Titel: Can PSA density be used to detect prostate cancer?
Auteur(s): Van der Kwast TH, Roobol MJ.
Tijdschrift: National Clinical Practice of Urology
Start- en eindpagina: 130 - 131

Titel: Tumour featurs in the control and screening arm of a randomized trial of prostate cancer.
Auteur(s): Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH.
Tijdschrift: European Urology
Start- en eindpagina: 70 - 75

Titel: The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Auteur(s): Vis AN, Schroder FH, van der Kwast TH.
Tijdschrift: European Urology
Start- en eindpagina: 258 - 265

Titel: The use of nomograms in the detection of prostate cancer.
Auteur(s): Roobol MJ.
Tijdschrift: Prostate
Start- en eindpagina: 1266 - 1267

Titel: Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Auteur(s): Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH.
Tijdschrift: European Urology
Start- en eindpagina: 475 - 482

Titel: Overall and Disease-Specific survival of patients with screen-detected prostate cancer in the European Randomized study of Screening for PC, section Rotterdam.
Auteur(s): de Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schroder FH.
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.
Auteur(s): Otto SJ, Schroder FH, de Koning HJ.
Tijdschrift: Journal of Clinical Oncology
Start- en eindpagina: 4184 - 4189

Titel: Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study.
Auteur(s): Bosch JL, Tilling K, Bohnen AM, Donovan JL.
Tijdschrift: Prostate
Start- en eindpagina: 335 - 343

Titel: Metastatic disease of screen-detected prostate cancer: characteristics at diagnosis
Auteur(s): Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH.
Tijdschrift: Cancer
Start- en eindpagina: 0 - 0

Titel: Overall survival in the intervention arm of a randomised controlled screening trial for prostate cancer compared to a clinically diagnosed cohort
Auteur(s): Vis AN, Roemeling S, Reedijk AMJ Otto SJ, Schröder FH.
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.
Auteur(s): Roemeling S, Roobol MJ, Kattan MW, Van der Kwast TH, Steyerberg EW, Schröder FH.
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Active surveillance for prostaet cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times and outcome
Auteur(s): Roemeling S, Roobol MJ, De Vries SJ, Wolters T, Gosselaar C, Van Leenders GJLH, SChröder FH
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics
Auteur(s): Gosselaar C, Roobol MJ, Roemeling S, Van der Kwast TH, Schröder FH.
Tijdschrift: Prostate
Start- en eindpagina: 0 - 0

Titel: Should we replace the Gleason score with the amount of high grade prostate cancer?
Auteur(s): Vis AN, Roemeling S, Kranse R, schröder FH, van der Kwast TH.
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Overall and disease-specific survival of patients with screen detected prostate cancer in the ERSPC, section Rotterdam
Auteur(s): De Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto s, De Koning HJ, Schröder FH
Tijdschrift: European Urology
Start- en eindpagina: 0 - 0

Titel: Long term follow-up of high grade intraepithelial prostatic neoplasia and atypical foci suspicious for carcinoma on sextant prostate needle biopsy
Auteur(s): Wolters T, Roobol MJ, Gosselaar C, Bangma CH, Schröder FH, van Leenders GJLH.
Tijdschrift: Urology
Start- en eindpagina: 0 - 0

Titel: pre-operative predictors of high grade prostate cancer in biopsy and radical prostatectomy speciments
Auteur(s): Wolters T, Roobol MJ, Gosselaar C, Bangma CH, Schröder FH, van Leenders GJLH
Tijdschrift: Urology
Start- en eindpagina: 0 - 0

Titel: Screening for prostate cancer without digital rectal examination: results after four years.
Start- en eindpagina: 0 - 0

Titel: Prostaatkankerscreening zonder rectaal toucher: resultaten na 4 jaar in de ERSPC
Start- en eindpagina: 0 - 0

Titel: Tumorkarakteristieken van prostaatkanker gedetecteerd op basis van rectaal toucher of PSA drempelwaarde
Start- en eindpagina: 0 - 0

Titel: The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer. Data from a multicentre study (ERSPC)
Auteur(s): Roobol MJ, Zappa M, Maatanen L, Ciatto S
Tijdschrift: Prostate
Start- en eindpagina: 0 - 0

Titel: PSA alone is not an appropriate surrogate marker of long-term therapeutic benefit in protate cancer trials
Auteur(s): Collette L, Burzykowski T, Schröder FH.
Tijdschrift: European Journal of Cancer Prevention
Start- en eindpagina: 1344 - 1350

Titel: Is PSA a valid surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer?
Auteur(s): Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH and the EORTC GU group.
Tijdschrift: Journal of Clinical Oncology
Start- en eindpagina: 6139 - 6140

Titel: PSA: a prognostic marker of survival in good prognosis metastatic prostate cancer?
Auteur(s): Collette L, De Reijke TM, Schröder FH, and EORTC GU group
Tijdschrift: European Urology
Start- en eindpagina: 182 - 189

Titel: Case-control studies in prostate cancer screening: an overview
Auteur(s): Otto S, Roobol MJ
Tijdschrift: European Urology
Start- en eindpagina: 219 - 227

Titel: Risk of cardiovascular mortality in prostate cancer patients in the rotterdam randomised screening trial
Auteur(s): Otto SJ, Roobol MJ, De Koning HJ
Tijdschrift: Journal of Clinical Oncology
Start- en eindpagina: 4184 - 1489

Titel: Gleason score, age, and screening: modelling and dedifferentiation in prostate cancer
Auteur(s): Draisma G, Postma R, Schröder FH, Van der Kwast TH, De Koning HJ.
Tijdschrift: International Journal of Cancer
Start- en eindpagina: 2366 - 2371

Titel: Side effects of localised prostate cancer treatment: are they valued differently by patients and healthy controls
Auteur(s): Korfage I, Koning HJ, Habbema JDF, Schröder FH, Essink-Bot ML.
Tijdschrift: British Journal of Urology International
Start- en eindpagina: 0 - 0

Titel: Anxiety and depression after prostate cancer diagnosis and treatment: 5 year follow-up
Auteur(s): Korfage IJ, Essink-Bot ML, Janssen ACJW, Schröder FH, Koning de HJ.
Tijdschrift: Urology
Start- en eindpagina: 0 - 0

Titel: De rol van familiaire prostaatkanker bij vroegopsporing. Resultaten van het Nederlandse deel van de ERSPC.
Auteur(s): Roobol MJ.
Tijdschrift: IKR Bulletin
Start- en eindpagina: 42 - 44

Titel: Watchful waiting versus expectant management at prostatic carcinoma (Dutch with English summary).
Auteur(s): de Vries SH, Bangma CH, Schröder FH.
Tijdschrift: Nederlands Tijdschrift voor Urologie
Start- en eindpagina: 4 - 0

Titel: Population based screening for prostate cancer: the pathology of early detected tumors. Part I.
Auteur(s): Hoedemaeker RF, van der Kwast TH, Schröder FH.
Tijdschrift: Nederlands Tijdschrift voor Urologie
Start- en eindpagina: 4 - 0

Titel: Bepaling van het individuele risico op prostaatkanker en indolente tumoren.
Auteur(s): Bangma CH, Roobol MJ, Schroder FH.
Tijdschrift: Nederlands Tijdschrift voor Urologie
Start- en eindpagina: 148 - 151

Presentatie
Dit item is dichtgeklapt
Dit item is opengeklapt

Titel: Vitamine und Micronährstoffe beim Prostatakarzinom (PC). Evidenz und Studien

Titel: Expectations of the medical practitioner

Titel: Prostatic biopsies. When and how?

Titel: Watchful Waiting (WW). Suggestions for an ERSPC policy

Titel: Overdiagnosis. Definitions and data. How to deal with it?

Titel: Screening for prostate cancer. Update and perspective

Titel: Endocrine treatment of Prostate Cancer

Titel: Antiandrogen monotherapy in prostate cancer. A standard of care?

Titel: Prostatic biopsies. When and How?

Titel: Rising PSA without treatment and after radical prostatectomy

Titel: Data from the European trial on Prostate cancer Screening

Titel: Screening for Prostate Cancer. What observational studies cannot show

Titel: PSA in clinical practice. use and misuse. Where do we stand?

Titel: Le point sur 'l'essai européen de dépistage

Titel: Screening for Prostate Cancer. Update and perspectives

Titel: Arguments against screening for Prostate Cancer

Titel: Past and current clinical studies of prevention of prostate cancer

Titel: Treatment options with rising PSA after primairy therapy

Titel: What speaks against screening for prostate cancer

Titel: New drugs and dietary supplements for prostate cancer. A development strategy

Titel: Das Prostatakarzinom. Epidemiologie und Screening

Titel: Prostate Cancer Screening. Status and Perspectives

Titel: Screening for Prostate Cancer. Arguments against population based screening

Titel: The case against prostate cancer screening

Titel: Screening for Prostate Cancer: an update

Titel: Screening for Prostate Cancer

Titel: Preliminary results of controlled trials of prostate cancer screening

Titel: Watchful waiting - an ERSPC policy proposal

Titel: Prognostic factors and mortality in prostate cancer

Titel: ERSPC Rotterdam 2003. Intermediate endpoints related findings

Titel: Screening and prevention of prostate cancer

Titel: Early detection of prostate cancer. Impact on mortality

Titel: Screen detection of prostate cancer in Japan and The Netherlands. Does it differ?

Titel: Screening for Prostate Cancer. Findings obtained in randomised studies

Titel: Screening for Prostate Cancer - An overview

Titel: SCreening for Prostate Cancer. An update including the ERSPC

Titel: Treatment of Gleason 7 - 10 localised prostate cancer

Titel: screening for prostate cancer. An update including the European Randomised Study of Screening for Prostate Cancer

Titel: Early diagnosis and screening for prostate cancer

Titel: Een broodje gezond en prostaatkanker

Titel: European Randomised Study of Screening for Prostate cancer - Rotterdam section. An update on Intermediate endpoints

Titel: PSA testing has reducted prostate cancer mortality. The PRO-position

Titel: Die Europäische Screeningstudie (ERSPC). Streitfragen.

Titel: Wohin geht der Weg der Fruüherkennung in 2010?

Titel: To screen or not to screen. Information from the ERSPC

Titel: Screening for prostate cancer

Titel: Quality of life with prostate cancer. Overdiagnosis and need for translational research

Titel: Screening for Prostate Cancer - an overview

Titel: Availability of an internationAL erspc biobank and methods of risk assessment

Titel: PRO's and CON's of screening for prostate cancer

Titel: Screening for prostate cancer

Titel: detection and prevention of prostate cancer. The impact of the ERSPC

Titel: Screening for prostate cancer - an update

Titel: Molecular tissue analysis to predict outcomes of patients with prostate cancer

Titel: Dieet en preventie van prostaatkanker

Titel: PSA based tertiary prevention studies of prostate cancer. Methodology and results

Titel: What is the optimal interval for screening

Titel: Screening for Prostate Cancer - The PRO position

Titel: PSA a valuable test in multiple screens for prostate cancewr?

Titel: Screening en prostaatkanker. Argumenten voor en tegen

Titel: watchful waiting prostate cancer

Titel: Rationale for a Watchful waiting program in prostate cancewr

Titel: Duration of follow-up in ERSPC. Is 10 years realistic?

Titel: Neue Ergebnisse der Europaischen randomisierten Studie zum Wert der Frühdiagnose beim Prostatakarzinom

Titel: Screening und Prostatakrebs. STatus 2005 und Zukunft

Titel: PSA is the best contemporary marker in screening for prostate cancer?

Titel: Rising PSA during follow-up of prostate cancer patients. What to do?

Titel: PSA in 2005. Use and misuse

Titel: Past and current clinical studies of prevention of Prostate cancer

Titel: Natuurlijk beloop en potentieel genezende behandeling van het locaal beperkt prostaatcarcinoom

Titel: Screening for Prostate cancer in 2005. Pro's and Con's

Titel: Overdiagnosis of prostate cancer through screening and how to deal with it

Titel: The role of PSA in secondary screening of the same population

Titel: The relation of PSA to cancer volume and Gleason scores in first and second round population based screening

Titel: How can early detection procedures be changed in a changing population

Titel: The ERSPC experience. Prostate cancer detection, overdiagnosis and aggressiveness

Titel: PSA velocity and aggressiveness in screen detected cancers

Titel: Prostaatcarcinoom: de waarde van PSA en het biopt

Titel: New developments in screening and early detection of prostate cancer

Titel: P-mark WP5. Contribution ERSPC

Titel: Stàrken und Schwàchen das PSA-wertes als Screening Parameters

Titel: Screening for Prostate Cancer

Titel: PSA velocity - a diagnostic tool or a measure of prsotate cancer aggressiveness

Titel: What speaks against screening for prostate cancer

Titel: Does overdiagnosis and overtreatment occur with PSA based screening and to what extent?

Titel: Predictioin of indolent prostate cancer: validation and updating of a prognositic nomogram

Titel: Early detection of prostate cancer: What to tell our patients?

Titel: The ERSPC and the Rotterdam experience

Titel: Je weet wat je PSA is - Wat dan?

Titel: Is PSA meten zinvol?

Titel: Validation and updating of the Kattan nomogram on the prediction on indolent cancer

Titel: Screening for Prostate cancer and the ERSPC

Titel: The ERSPC

Titel: Overview ERSPC 2006 - risk analysis

Titel: Opportunistic screening for prostate cancer. What to tell our patients?

Titel: Diagnose, behandeling en prognose van familiaire prostaatkanker in een screeningspopulatie

Titel: Biochemische progressie in de screening arm van de ERSPC vergeleken met de controle arm

Titel: Contaminatie in de controle arm van de ERSPC

Titel: Prostaatkanker screening: hetzelfde protocol in de eerste en vervolg screeningronden?

Titel: Family history and prostate cancer screening ERSPC rotterdam

Titel: Prostate cancer screening: the same screening protocol at initial and second screening round?

Titel: Is further testing necessary in men with PSA levels <= 1.0 ng/ml, ERSPC section Rotterdam

Titel: First results of re-screening after 8 years in ERSPC section Rotterdam

Titel: A previous negative sextant biopsy as predictor for biopsy outcome at the third screening round

Titel: Incidence of prostate cancers detected in men who refused biopsy at initial screen ing (1993 -1999) ERSPC Rotterdam

Titel: Surrogacy in prostate cancer. Scope of the problem and proposals

Titel: Second round testing for prostate cancer

Titel: Influence of deferred treatment with curable intent on progression free survival rates in prostate cancer

Titel: Metastatic disease rates after radical prostatectomy and radiotherapy in screen detected prostate cancer

Titel: Metastasen van screen gedetecteerde prostaatkanker: karakteristieken bij diagnose

Titel: Contaminatie in de controle arm van de ERSPC

Titel: Death from Screen detected prostate cancer: the demographics at diagnosis

Titel: Preliminary results of the second screening round of hte ERSPC

Titel: A positive family history at repeat prostate cancer screening

Titel: Final results of hte intital and second screening round of ERSPC section rotterdam

Titel: The use of an upper age limit in prostate cancer screening

Titel: PSA velocity and the detection of clinically significant cancers in an early detection setting, ERSPC Rotterdam

Overig
Dit item is dichtgeklapt
Dit item is opengeklapt

Titel: Prostate Cancer Screening: tests and algorithms

Titel: Population based screening for prostate cancer: prognostic findings of two subsequent screening rounds

Titel: Localised prostate cancer and quality of life: screening treatment and methodological issues

Titel: prostate cancer: prognostic factors, markers of outcome and design of clinical trials

Titel: Population based screening for prostate cancer

Naar boven
Direct naar: InhoudDirect naar: NavigatieDirect naar: Onderkant website